Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248)

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 251-258

  Mosure, Kathleen W ^a   Henderson, Arris J ^a   Klunk, Lewis J ^a   Knipe, Jay O ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biodistribution; Doxorubicin; Immunoconjugate; Tumor bearing mice

Indexed keywords

ANTIBODY CONJUGATE; BMS 182248; DOXORUBICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOCONJUGATES; INJECTIONS, INTRAVENOUS; LIVER; LUNG NEOPLASMS; LYSOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; MYOCARDIUM; NEOPLASM TRANSPLANTATION;

EID: 0030923296     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050655     Document Type: Article

References (29)

1. 14C-labelled 4′-epidoxorubicin and doxorubicin in the rat. Cancer Chemother Pharmacol 12: 157
2. Braslawsky GR, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T, Greenfield RS (1991) Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol Immunother 33: 367
3. Broggini M, Colombo T, Martini A, Donelli MG (1980) Studies on the comparative distribution and biliary excretion of doxorubicin and 4′-epi-doxorubicin in mice and rats. Cancer Treat Rep 64: 897
4. Brown JE, Patterson LH, Williamson J, Brown JR (1992) Method for analysis, and distribution profile, of covalently-linked ferritin-daunorubicin conjugate in the blood of trypanosome-infected mice. J Pharm Pharmacol 44: 48
5. Comereski CR, Peden WM, Davidson TJ, Warner GL, Hirth RS, Franz JD (1994) BR96-doxorubicin conjugate (BMS 182248) versus doxorubicin: a comparative toxicity assessment in rats. Toxicol Pathol 22: 473
6. Cummings J, Merry S, Willmott N (1986) Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a subcutaneously growing Ridgeway osteogenic sarcoma. Eur J Cancer Clin Oncol 22: 451
7. Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, Frincke JM (1986) Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res 46: 4886
8. Dillman RO, Johnson DE, Shawler DL, Koziol JA (1988) Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48: 6097
9. Formelli F, Carsana R, Pollini C (1987) Pharmacokinetics of 4′-deoxy-4′-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. Cancer Res 47: 5401
10. y specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 142: 607
11. Gupta PK (1990) Drug targeting in cancer chemotherapy: a clinical perspective. J Pharm Sci 79: 949
12. y-related cell surface antigens. Cancer Res 50: 2183
13. Kaneko T, Willner D, Monkovic I, Knipe JO, Braslawsky GR, Greenfield RS, Vyas DM (1991) New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjugate Chem 2: 133
14. Lardeux B, Gouhot B, Forestier M (1983) Improved recovery of rat liver fractions enriched in lysosomes by specific alteration of the sedimentation properties of mitochondria. Anal Biochem 131: 160
15. Mueller BM, Wrasidlo WA, Reisfeld RA (1990) Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjugate Chem 1: 325
16. Mueller BM, Reisfeld RA, Silveira MH, Duncan JD, Wrasidlo WA (1991) Preclinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells. Antibody Immunoconjugates Radiopharm 4: 99
17. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4: 30
18. Peters JH, Gordon GR, Kashiwase D, Acton EM (1981) Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmacol 7: 65
19. Pietersz GA, Krauer K (1994) Antibody-targeted drugs for the therapy of cancer. J Drug Target 2: 183
20. Pietersz GA, McKenzie IFC (1992) Antibody conjugates for the treatment of cancer. Immunol Rev 129: 57
21. Schreiber GJ, Hellstrom KE, Hellstrom I (1992) An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res 52: 3262
22. Seymour LW, Ulbrich K, Strohalm J, Kopecek J, Duncan R (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol 39: 1125
23. Shinozawa S, Mimaki Y, Araki Y (1980) Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Erhlich carcinoma-bearing mice by high-performance liquid chromatography. J Chromatogr 196: 463
24. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I, Hellstrom KE (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261: 212
25. Trouet A, Masquelier M, Baurain R, Deprez-De Campeneere D (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomal drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci USA 79: 626
26. Upeslacis J, Hinman L (1988) Chemical modification of antibodies for cancer chemotherapy. Annu Rep Med Chem 23: 151
27. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR,Greenfield RS, Kaneko T, Firestone RA (1993) (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem 4: 521
28. Yang HM, Reisfeld RA (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sc USA 85: 1189
29. Yang HM, Reisfeld, RA (1988) Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan. J Natl Cancer Inst 80: 54